title: [Impact of galectin 3 as myofibrosis marker in clinical cardiology].
abstract: Galectin 3 is a protein secreted by activated macrophages and has a role in development of fibrosis in injured tissues. Experimental studies showed increased galectin 3 secretion in the context of cardiac hypertrophy and heart failure models. Several clinical studies identified galectin 3 to be a biomarker of cardiovascular diseases in the field of diagnosis, risk stratification, monitoring therapy response and predicting short-term and long-term prognosis. Particularly, the additional prognostic information of galectin 3 as assessed together with NT-proBNP was established in acute and chronic heart failure.
authors.forename: Filip
authors.initials: F
authors.lastname: Málek
mesh_terms: D015415:Biomarkers / Q000378:metabolism*; D002908:Chronic Disease; D037502:Galectin 3 / Q000378:metabolism*; D006333:Heart Failure / Q000378:metabolism*; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000378:metabolism*; D010446:Peptide Fragments / Q000378:metabolism*; D011379:Prognosis
chemical_list: D015415:Biomarkers; D037502:Galectin 3; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain